Fig. 2.

Immunoenhancing synergistic effect of the C-terminal proTα fragments with IL-2 to healthy donors’ (a) and cancer patients’ (b) PBMC cytotoxicity. PBMC from both groups were incubated for 3 days with IL-2 (20 IU/ml) and proTα (160 ng/ml) or each of proTα’s peptides, at doses as indicated in ‘‘Materials and Methods’’, and tested as effectors for cytotoxicity against K562 and Daudi targets. In all experiments, the effector-to-target cell ratio was 40:1. Data are presented as mean % specific cytotoxicity ± SD from 17 and 14 healthy individuals and cancer patients tested, respectively. Other details as in Fig. 1